Bengaluru, Karnataka, India, April 2026 – Mandar Ghatnekar has started a new role as Chief Technology Officer at Biocon, marking a significant milestone in his journey as a technology and digital transformation leader in the life sciences sector.
In this role, he will lead technology strategy, digital innovation, and enterprise transformation initiatives, supporting Biocon’s mission to enhance global healthcare through innovative and affordable biopharmaceutical solutions.
Prior to joining Biocon, Mandar Ghatnekar served as Global Head of IT & Digital Transformation at Biocon Biologics, where he led the development and execution of IT and digital strategies aligned with global healthcare delivery goals, leveraging technologies such as AI and cloud computing to drive innovation and operational efficiency.
He also held the role of Chief Digital Transformation Officer, playing a pivotal role in advancing digital transformation initiatives across the organization and enabling data-driven decision-making at scale.
Before his tenure at Biocon, he spent over a decade with Accenture as Managing Director, where he led large-scale enterprise transformation programs, built data and cloud solution capabilities, and managed global delivery teams serving clients across life sciences, healthcare, and other industries.
Earlier in his career, he worked with Johnson & Johnson, where he contributed to global IT process standardization and compliance frameworks, and with Infosys Technologies Limited, where he led consulting and implementation projects across life sciences and pharmaceutical domains.
He began his professional journey in biotechnology and consulting roles, building a strong foundation in bioprocess technology, computational biology, and life sciences innovation.
With extensive experience across digital transformation, cloud, AI, and life sciences technology, Mandar Ghatnekar brings a powerful blend of technology leadership and domain expertise to his new role.
Biocon is India’s largest innovation-led biopharmaceutical company, serving customers in over 120 countries. The company is focused on delivering affordable and accessible healthcare solutions, particularly in areas of chronic diseases with high unmet medical needs.
With strong capabilities in biosimilars, biologics, and fermentation-based products, Biocon has built a globally recognized portfolio and continues to lead innovation in diabetes, oncology, and autoimmune therapies. Through its subsidiary Syngene, it also offers end-to-end discovery and development services to the global life sciences industry.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work









